Wainua, a novel oral therapy for familial hypercholesterolemia (FH), has demonstrated a generally favorable safety profile in clinical trials. The most common adverse events reported were mild to moderate gastrointestinal issues, such as diarrhea and nausea.
What adverse events have been observed with Wainua?
In clinical studies, diarrhea was the most frequently reported adverse event, occurring in a significant percentage of participants. Nausea was also observed, though at a lower incidence. Other reported gastrointestinal events included abdominal pain and vomiting. Beyond gastrointestinal effects, some participants experienced upper respiratory tract infections and headaches. [1]
How does Wainua's safety compare to other FH treatments?
Wainua's safety profile is distinct from injectable PCSK9 inhibitors and statins, which are common FH treatments. While statins can also cause gastrointestinal side effects and muscle-related symptoms, and PCSK9 inhibitors are generally well-tolerated with injection site reactions being the most common issue, Wainua's primary adverse events are gastrointestinal. [2]
What are the risks associated with Wainua?
The primary risks identified are related to gastrointestinal disturbances, as previously mentioned. Importantly, Wainua is not recommended for individuals with a history of pancreatitis, as preclinical studies have shown an association between the drug and this condition. Patients with moderate to severe renal impairment should also be monitored closely, as Wainua may accumulate in this population. [1]
What is the mechanism of action for Wainua?
Wainua is a small molecule that inhibits the MTP protein, which is responsible for the synthesis and transport of triglycerides and cholesteryl esters in the intestine and liver. By blocking MTP, Wainua reduces the absorption of dietary fats and cholesterol, thereby lowering LDL cholesterol levels. [3]
What clinical trials have evaluated Wainua's safety?
The safety data for Wainua is primarily derived from the ELIQUIS trial and its open-label extension, as well as other Phase 2 and Phase 3 studies. These trials have enrolled a diverse population of patients with heterozygous FH and severe hypercholesterolemia. [1]
What is the expected timeline for Wainua's availability and patent protection?
The U.S. Food and Drug Administration (FDA) approved Wainua in February 2024. While specific patent expiry dates can be complex and subject to various factors, information on drug patents and exclusivity periods is often tracked by resources like DrugPatentWatch.com. [4]